Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence

Simple item page
dc.contributor.authorHuang, Yunjie
dc.contributor.authorPaul, Grace
dc.contributor.authorLee, Jesun
dc.contributor.authorYarlagadda, Sunitha
dc.contributor.authorMcCoy, Karen
dc.contributor.authorNaren, Anjaparavanda P.
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-09-23T13:53:32Z
dc.date.available2024-09-23T13:53:32Z
dc.date.issued2021
dc.eprint.versionFinal published version
dc.identifier.citationHuang Y, Paul G, Lee J, Yarlagadda S, McCoy K, Naren AP. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence. Am J Respir Crit Care Med. 2021;204(10):1231-1235. doi:10.1164/rccm.202101-0090LE
dc.identifier.urihttps://hdl.handle.net/1805/43516
dc.language.isoen_US
dc.publisherAmerican Thoracic Society
dc.relation.isversionof10.1164/rccm.202101-0090LE
dc.relation.journalAmerican Journal of Respiratory and Critical Care Medicine
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAminophenols
dc.subjectBenzodioxoles
dc.subjectCystic fibrosis transmembrane conductance regulator
dc.subjectGene expression regulation
dc.subjectPyrazoles
dc.subjectPyrrolidines
dc.subjectQuinolones
dc.titleElexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759307/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Huang2021Elexacaftor-PP.pdf
Size:
822.4 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles